Research Article
Synthesis and Biological Evaluation of Novel Piperazine Containing Hydrazone Derivatives
Table 2
Cholinesterase inhibitory activity and IC50 values (µg/mL) of compounds (3a–k).
| Compound | AChE | BuChE | 80 mg/mL (% inhibition) | IC50 mg/mL | 80 mg/mL (% inhibition) | IC50 mg/mL |
| 3a | 42.30 ± 4.70 | >80 | 40.11 ± 3.72 | >80 | 3b | 16.30 ± 2.43 | >80 | 20.16 ± 2.86 | >80 | 3c | 57.30 ± 0.66 | 29.5 ± 2.12 | 46.56 ± 3.20 | >80 | 3d | — | — | 15.53 ± 3.84 | >80 | 3e | 33.37 ± 4.45 | >80 | 33.07 ± 3.41 | >80 | 3f | 37.22 ± 3.46 | >80 | 27.63 ± 0.86 | >80 | 3g | 24.74 ± 1.81 | >80 | 31.60 ± 2.05 | >80 | 3h | 12.11 ± 2.80 | >80 | — | — | 3i | 35.14 ± 4.43 | >80 | — | — | 3j | 11.39 ± 0.16 | >80 | — | — | 3k | 23.85 ± 1.85 | >80 | — | — | Galantamine | nt | 0.46 ± 0.08 | nt | 6.28 ± 0.32 |
|
|
—: not active. nt: nontested.
|